Blog
RSS FeedPosted by Michael Wonder on 13 Mar 2019
Drug price watchdog ICER dives into Trump fueled pharma rebate debate
13 March 2019 - With public and political winds blowing in the same direction, significant reform of the complicated U.S. ...
Posted by Michael Wonder on 12 Mar 2019
Institute for Clinical and Economic Review publishes white paper on alternative models for pharmaceutical rebates
12 March 2019 - Paper explores how reforming or eliminating rebates may affect drug pricing, patient access, and incentives for future ...
Posted by Michael Wonder on 12 Mar 2019
Overview of cost-effectiveness analysis
11 March 2019 - Health care decision makers, including patients, clinicians, hospitals, private health systems, and public payers (eg, Medicare), are ...
Posted by Michael Wonder on 22 Feb 2019
ICER’s assessment finds Spinraza and Zolgensma provide substantial health benefits for people with spinal muscular atrophy
22 February 2019 - Current pricing of Spinraza would require a substantial discount to meet traditional cost-effectiveness ranges; Zolgensma’s value-based price ...
Posted by Michael Wonder on 22 Feb 2019
ICER to publish upcoming assessment on additive cardiovascular disease therapies
22 February 2019 - Report will be subject of Midwest CEPAC meeting in September; open input now being accepted until ...
Posted by Michael Wonder on 15 Feb 2019
ICER publishes final new evidence update for alirocumab, a PCSK9 inhibitor for treating high cholesterol
15 February 2019 - Based on new analyses of published results of the ODYSSEY Outcomes trial, alirocumab would meet cost-effectiveness thresholds ...
Posted by Michael Wonder on 23 Jan 2019
ICER launches international collaborative to develop new methods to guide value-based pricing of potential cures
23 January 2019 - NICE in the UK and CADTH in Canada among international agencies participating; public input on key methodological ...
Posted by Michael Wonder on 21 Jan 2019
New whitepaper identifies limitations in using ICER’s “potential budget impact” work to guide private payer budget decisions
18 January 2019 - A new whitepaper authored by Bruce Pyenson and colleagues from Milliman explains why ICER potential budget ...
Posted by Michael Wonder on 11 Jan 2019
ICER posts draft scoping document for the assessment of treatments for Duchenne muscular dystrophy
11 January 2019 - Document open to public comment until 1 February 2019. ...
Posted by Michael Wonder on 21 Dec 2018
Institute for Clinical and Economic Review releases draft evidence report on treatments for spinal muscular atrophy
20 December 2018 - Public comment period now open until 31 January 2019; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 20 Dec 2018
Institute for Clinical and Economic Review provides policy recommendations for biologic treatments for uncontrolled asthma
20 December 2018 - Expert roundtable suggests that lower prices, needed to align pricing fairly with the added value for patients, ...
Posted by Michael Wonder on 13 Dec 2018
ICER describes for patients and policy makers why the QALY is considered the best way to reward the care that improves patients’ lives
12 December 2018 - ICER reiterates its commitment to equality and will highlight measures of cost-effectiveness that value any extension of ...
Posted by Michael Wonder on 13 Dec 2018
Institute for Clinical and Economic Review to publish upcoming assessment on treatments for Duchenne muscular dystrophy
13 December 2018 - Report will be subject of New England CEPAC meeting in July 2019; Open Input now being accepted ...
Posted by Michael Wonder on 03 Dec 2018
Institute for Clinical and Economic Review provides policy recommendations for extended-release treatments for opioid use disorder
3 December 2018 - CAM2038 could reach fair value-based price if launched with annual price less than $5,300. ...
Posted by Michael Wonder on 29 Nov 2018
Amgen cuts Repatha’s price by 60 percent. Will value-based pricing support value-based patient access?
28 November 2018 - Recently, Amgen announced a 60% reduction in the list price of its PCSK9 drug Repatha for patients ...